A Prospective, Single-blinded, Multi-center, Randomized, Controlled, Registered Clinical Trial on the Efficacy and Safety of Sirolimus-eluting Stent (MiStent System) in the Treatment of Patients With Coronary Heart Disease

Trial Profile

A Prospective, Single-blinded, Multi-center, Randomized, Controlled, Registered Clinical Trial on the Efficacy and Safety of Sirolimus-eluting Stent (MiStent System) in the Treatment of Patients With Coronary Heart Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease
  • Focus Registrational; Therapeutic Use
  • Acronyms DESSOLVE-C
  • Sponsors Micell Technologies
  • Most Recent Events

    • 15 Dec 2016 Planned End Date changed from 1 Dec 2020 to 1 Apr 2022.
    • 15 Dec 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2018.
    • 31 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top